Institutional shares held 85.8 Million
1.39M calls
1.45M puts
Total value of holdings $47.4B
$767M calls
$801M puts
Market Cap $59.2B
107,190,000 Shares Out.
Institutional ownership 80.06%
# of Institutions 1,469


Latest Institutional Activity in REGN

Top Purchases

Q2 2025
Baader Bank Aktiengesellschaft Shares Held: 14.3K ($7.9M)
Q2 2025
Guo Line Advisory Pte LTD Shares Held: 67.3K ($37.2M)
Q2 2025
Sovran Advisors, LLC Shares Held: 5.02K ($2.77M)
Q2 2025
Massmutual Trust CO Fsb Shares Held: 8.84K ($4.89M)
Q2 2025
Swedbank Ab Shares Held: 228K ($126M)

Top Sells

Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 9.66K ($5.34M)
Q2 2025
Livforsakringsbolaget Skandia, Omsesidigt Shares Held: 872 ($482K)
Q2 2025
Procyon Advisors, LLC Shares Held: 531 ($293K)
Q2 2025
Sumitomo Mitsui Ds Asset Management Company, LTD Shares Held: 14.3K ($7.88M)
Q2 2025
Harbor Investment Advisory, LLC Shares Held: 2.68K ($1.48M)

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.


Insider Transactions at REGN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
81K Shares
From 25 Insiders
Grant, award, or other acquisition 17K shares
Exercise of conversion of derivative security 64K shares
Acquisition or disposition by will or laws 14 shares
Sell / Disposition
80.4K Shares
From 19 Insiders
Payment of exercise price or tax liability 42.1K shares
Open market or private sale 34.5K shares
Bona fide gift 3.79K shares

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN